| Dr Jeffrey R Wasserman, DO | |
|
206 2nd St E, Bradenton, FL 34208-1042 | |
| (941) 955-4101 | |
| Not Available |
| Full Name | Dr Jeffrey R Wasserman |
|---|---|
| Gender | Male |
| Speciality | Diagnostic Radiology |
| Experience | 27 Years |
| Location | 206 2nd St E, Bradenton, Florida |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1437104676 | NPI | - | NPPES |
| 267671100 | Medicaid | FL |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0202X | Radiology - Diagnostic Radiology | OS8900 (Florida) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Sarasota Memorial Hospital | Sarasota, FL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Intercoastal Medical Group Inc | 6305730912 | 165 |
| Mori Bean And Brooks Inc | 8820077878 | 633 |
News Archive
A recent study by researchers at the University of Miami, Miami VA Healthcare System and Express Gene and published on the preprint server medRxiv in September 2020 reports on the prognostic significance of the anti-N Immunoglobulin G (IgG) antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
GTC Biotherapeutics, Inc.'s ("GTC", NASDAQ: GTCB) received a letter from the Listing Qualifications Staff of The NASDAQ Stock Market (the "Staff Determination") on September 17, 2009, indicating that unless GTC requests a hearing before the NASDAQ Listing Qualifications Panel (the "Panel"), the Company's securities would be subject to delisting from The NASDAQ Capital Market due to non-compliance with the $35 million market value of listed securities requirement as set forth in Listing Rule 5550(b)(2).
The newest generation of "virtual biopsy" colonoscopy probes being tested at the Mayo Clinic campus in Florida demonstrate that it might soon be possible to use such a device to determine whether a colon polyp is benign and not remove it for biopsy. Currently, all colon polyps are extracted during a colonoscopy and sent to a pathologist for examination, which adds time, expense, and some surgical risk, to the procedure.
Scientific advances at The Scripps Research Institute were key to laying the foundation for the new drug Benlysta® (belimumab), approved today by the U.S. Food and Drug Administration. Benlysta®, which treats the most common type of lupus, is the first in a new class of pharmaceuticals that prevents the body from attacking its own critical tissues.
Invention of the first integrated circularly polarized light detector on a silicon chip opens the door for development of small, portable sensors that could expand the use of polarized light for drug screening, surveillance, optical communications and quantum computing, among other potential applications.
› Verified 9 days ago
| Entity Name | Diagnostic Clinic Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1407851314 PECOS PAC ID: 4082526280 Enrollment ID: O20031105000430 |
News Archive
A recent study by researchers at the University of Miami, Miami VA Healthcare System and Express Gene and published on the preprint server medRxiv in September 2020 reports on the prognostic significance of the anti-N Immunoglobulin G (IgG) antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
GTC Biotherapeutics, Inc.'s ("GTC", NASDAQ: GTCB) received a letter from the Listing Qualifications Staff of The NASDAQ Stock Market (the "Staff Determination") on September 17, 2009, indicating that unless GTC requests a hearing before the NASDAQ Listing Qualifications Panel (the "Panel"), the Company's securities would be subject to delisting from The NASDAQ Capital Market due to non-compliance with the $35 million market value of listed securities requirement as set forth in Listing Rule 5550(b)(2).
The newest generation of "virtual biopsy" colonoscopy probes being tested at the Mayo Clinic campus in Florida demonstrate that it might soon be possible to use such a device to determine whether a colon polyp is benign and not remove it for biopsy. Currently, all colon polyps are extracted during a colonoscopy and sent to a pathologist for examination, which adds time, expense, and some surgical risk, to the procedure.
Scientific advances at The Scripps Research Institute were key to laying the foundation for the new drug Benlysta® (belimumab), approved today by the U.S. Food and Drug Administration. Benlysta®, which treats the most common type of lupus, is the first in a new class of pharmaceuticals that prevents the body from attacking its own critical tissues.
Invention of the first integrated circularly polarized light detector on a silicon chip opens the door for development of small, portable sensors that could expand the use of polarized light for drug screening, surveillance, optical communications and quantum computing, among other potential applications.
› Verified 9 days ago
| Entity Name | Medical Technology Transfer Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1104947217 PECOS PAC ID: 1658265079 Enrollment ID: O20040209000360 |
News Archive
A recent study by researchers at the University of Miami, Miami VA Healthcare System and Express Gene and published on the preprint server medRxiv in September 2020 reports on the prognostic significance of the anti-N Immunoglobulin G (IgG) antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
GTC Biotherapeutics, Inc.'s ("GTC", NASDAQ: GTCB) received a letter from the Listing Qualifications Staff of The NASDAQ Stock Market (the "Staff Determination") on September 17, 2009, indicating that unless GTC requests a hearing before the NASDAQ Listing Qualifications Panel (the "Panel"), the Company's securities would be subject to delisting from The NASDAQ Capital Market due to non-compliance with the $35 million market value of listed securities requirement as set forth in Listing Rule 5550(b)(2).
The newest generation of "virtual biopsy" colonoscopy probes being tested at the Mayo Clinic campus in Florida demonstrate that it might soon be possible to use such a device to determine whether a colon polyp is benign and not remove it for biopsy. Currently, all colon polyps are extracted during a colonoscopy and sent to a pathologist for examination, which adds time, expense, and some surgical risk, to the procedure.
Scientific advances at The Scripps Research Institute were key to laying the foundation for the new drug Benlysta® (belimumab), approved today by the U.S. Food and Drug Administration. Benlysta®, which treats the most common type of lupus, is the first in a new class of pharmaceuticals that prevents the body from attacking its own critical tissues.
Invention of the first integrated circularly polarized light detector on a silicon chip opens the door for development of small, portable sensors that could expand the use of polarized light for drug screening, surveillance, optical communications and quantum computing, among other potential applications.
› Verified 9 days ago
| Entity Name | Intercoastal Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1578537767 PECOS PAC ID: 6305730912 Enrollment ID: O20040212000600 |
News Archive
A recent study by researchers at the University of Miami, Miami VA Healthcare System and Express Gene and published on the preprint server medRxiv in September 2020 reports on the prognostic significance of the anti-N Immunoglobulin G (IgG) antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
GTC Biotherapeutics, Inc.'s ("GTC", NASDAQ: GTCB) received a letter from the Listing Qualifications Staff of The NASDAQ Stock Market (the "Staff Determination") on September 17, 2009, indicating that unless GTC requests a hearing before the NASDAQ Listing Qualifications Panel (the "Panel"), the Company's securities would be subject to delisting from The NASDAQ Capital Market due to non-compliance with the $35 million market value of listed securities requirement as set forth in Listing Rule 5550(b)(2).
The newest generation of "virtual biopsy" colonoscopy probes being tested at the Mayo Clinic campus in Florida demonstrate that it might soon be possible to use such a device to determine whether a colon polyp is benign and not remove it for biopsy. Currently, all colon polyps are extracted during a colonoscopy and sent to a pathologist for examination, which adds time, expense, and some surgical risk, to the procedure.
Scientific advances at The Scripps Research Institute were key to laying the foundation for the new drug Benlysta® (belimumab), approved today by the U.S. Food and Drug Administration. Benlysta®, which treats the most common type of lupus, is the first in a new class of pharmaceuticals that prevents the body from attacking its own critical tissues.
Invention of the first integrated circularly polarized light detector on a silicon chip opens the door for development of small, portable sensors that could expand the use of polarized light for drug screening, surveillance, optical communications and quantum computing, among other potential applications.
› Verified 9 days ago
| Entity Name | Radiology Associates Of Tampa Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477720837 PECOS PAC ID: 2264410471 Enrollment ID: O20040713000412 |
News Archive
A recent study by researchers at the University of Miami, Miami VA Healthcare System and Express Gene and published on the preprint server medRxiv in September 2020 reports on the prognostic significance of the anti-N Immunoglobulin G (IgG) antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
GTC Biotherapeutics, Inc.'s ("GTC", NASDAQ: GTCB) received a letter from the Listing Qualifications Staff of The NASDAQ Stock Market (the "Staff Determination") on September 17, 2009, indicating that unless GTC requests a hearing before the NASDAQ Listing Qualifications Panel (the "Panel"), the Company's securities would be subject to delisting from The NASDAQ Capital Market due to non-compliance with the $35 million market value of listed securities requirement as set forth in Listing Rule 5550(b)(2).
The newest generation of "virtual biopsy" colonoscopy probes being tested at the Mayo Clinic campus in Florida demonstrate that it might soon be possible to use such a device to determine whether a colon polyp is benign and not remove it for biopsy. Currently, all colon polyps are extracted during a colonoscopy and sent to a pathologist for examination, which adds time, expense, and some surgical risk, to the procedure.
Scientific advances at The Scripps Research Institute were key to laying the foundation for the new drug Benlysta® (belimumab), approved today by the U.S. Food and Drug Administration. Benlysta®, which treats the most common type of lupus, is the first in a new class of pharmaceuticals that prevents the body from attacking its own critical tissues.
Invention of the first integrated circularly polarized light detector on a silicon chip opens the door for development of small, portable sensors that could expand the use of polarized light for drug screening, surveillance, optical communications and quantum computing, among other potential applications.
› Verified 9 days ago
| Entity Name | Tower Imaging Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1467654244 PECOS PAC ID: 2860470077 Enrollment ID: O20040713000446 |
News Archive
A recent study by researchers at the University of Miami, Miami VA Healthcare System and Express Gene and published on the preprint server medRxiv in September 2020 reports on the prognostic significance of the anti-N Immunoglobulin G (IgG) antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
GTC Biotherapeutics, Inc.'s ("GTC", NASDAQ: GTCB) received a letter from the Listing Qualifications Staff of The NASDAQ Stock Market (the "Staff Determination") on September 17, 2009, indicating that unless GTC requests a hearing before the NASDAQ Listing Qualifications Panel (the "Panel"), the Company's securities would be subject to delisting from The NASDAQ Capital Market due to non-compliance with the $35 million market value of listed securities requirement as set forth in Listing Rule 5550(b)(2).
The newest generation of "virtual biopsy" colonoscopy probes being tested at the Mayo Clinic campus in Florida demonstrate that it might soon be possible to use such a device to determine whether a colon polyp is benign and not remove it for biopsy. Currently, all colon polyps are extracted during a colonoscopy and sent to a pathologist for examination, which adds time, expense, and some surgical risk, to the procedure.
Scientific advances at The Scripps Research Institute were key to laying the foundation for the new drug Benlysta® (belimumab), approved today by the U.S. Food and Drug Administration. Benlysta®, which treats the most common type of lupus, is the first in a new class of pharmaceuticals that prevents the body from attacking its own critical tissues.
Invention of the first integrated circularly polarized light detector on a silicon chip opens the door for development of small, portable sensors that could expand the use of polarized light for drug screening, surveillance, optical communications and quantum computing, among other potential applications.
› Verified 9 days ago
| Entity Name | Mori Bean And Brooks Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093782070 PECOS PAC ID: 8820077878 Enrollment ID: O20040714001317 |
News Archive
A recent study by researchers at the University of Miami, Miami VA Healthcare System and Express Gene and published on the preprint server medRxiv in September 2020 reports on the prognostic significance of the anti-N Immunoglobulin G (IgG) antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
GTC Biotherapeutics, Inc.'s ("GTC", NASDAQ: GTCB) received a letter from the Listing Qualifications Staff of The NASDAQ Stock Market (the "Staff Determination") on September 17, 2009, indicating that unless GTC requests a hearing before the NASDAQ Listing Qualifications Panel (the "Panel"), the Company's securities would be subject to delisting from The NASDAQ Capital Market due to non-compliance with the $35 million market value of listed securities requirement as set forth in Listing Rule 5550(b)(2).
The newest generation of "virtual biopsy" colonoscopy probes being tested at the Mayo Clinic campus in Florida demonstrate that it might soon be possible to use such a device to determine whether a colon polyp is benign and not remove it for biopsy. Currently, all colon polyps are extracted during a colonoscopy and sent to a pathologist for examination, which adds time, expense, and some surgical risk, to the procedure.
Scientific advances at The Scripps Research Institute were key to laying the foundation for the new drug Benlysta® (belimumab), approved today by the U.S. Food and Drug Administration. Benlysta®, which treats the most common type of lupus, is the first in a new class of pharmaceuticals that prevents the body from attacking its own critical tissues.
Invention of the first integrated circularly polarized light detector on a silicon chip opens the door for development of small, portable sensors that could expand the use of polarized light for drug screening, surveillance, optical communications and quantum computing, among other potential applications.
› Verified 9 days ago
| Entity Name | Advanced Imaging Of Port Charlotte Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1659365021 PECOS PAC ID: 8123084134 Enrollment ID: O20041201000998 |
News Archive
A recent study by researchers at the University of Miami, Miami VA Healthcare System and Express Gene and published on the preprint server medRxiv in September 2020 reports on the prognostic significance of the anti-N Immunoglobulin G (IgG) antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
GTC Biotherapeutics, Inc.'s ("GTC", NASDAQ: GTCB) received a letter from the Listing Qualifications Staff of The NASDAQ Stock Market (the "Staff Determination") on September 17, 2009, indicating that unless GTC requests a hearing before the NASDAQ Listing Qualifications Panel (the "Panel"), the Company's securities would be subject to delisting from The NASDAQ Capital Market due to non-compliance with the $35 million market value of listed securities requirement as set forth in Listing Rule 5550(b)(2).
The newest generation of "virtual biopsy" colonoscopy probes being tested at the Mayo Clinic campus in Florida demonstrate that it might soon be possible to use such a device to determine whether a colon polyp is benign and not remove it for biopsy. Currently, all colon polyps are extracted during a colonoscopy and sent to a pathologist for examination, which adds time, expense, and some surgical risk, to the procedure.
Scientific advances at The Scripps Research Institute were key to laying the foundation for the new drug Benlysta® (belimumab), approved today by the U.S. Food and Drug Administration. Benlysta®, which treats the most common type of lupus, is the first in a new class of pharmaceuticals that prevents the body from attacking its own critical tissues.
Invention of the first integrated circularly polarized light detector on a silicon chip opens the door for development of small, portable sensors that could expand the use of polarized light for drug screening, surveillance, optical communications and quantum computing, among other potential applications.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jeffrey R Wasserman, DO 8374 Market St, Box 502, Lakewood Ranch, FL 34202-5137 Ph: (941) 955-4101 | Dr Jeffrey R Wasserman, DO 206 2nd St E, Bradenton, FL 34208-1042 Ph: (941) 955-4101 |
News Archive
A recent study by researchers at the University of Miami, Miami VA Healthcare System and Express Gene and published on the preprint server medRxiv in September 2020 reports on the prognostic significance of the anti-N Immunoglobulin G (IgG) antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
GTC Biotherapeutics, Inc.'s ("GTC", NASDAQ: GTCB) received a letter from the Listing Qualifications Staff of The NASDAQ Stock Market (the "Staff Determination") on September 17, 2009, indicating that unless GTC requests a hearing before the NASDAQ Listing Qualifications Panel (the "Panel"), the Company's securities would be subject to delisting from The NASDAQ Capital Market due to non-compliance with the $35 million market value of listed securities requirement as set forth in Listing Rule 5550(b)(2).
The newest generation of "virtual biopsy" colonoscopy probes being tested at the Mayo Clinic campus in Florida demonstrate that it might soon be possible to use such a device to determine whether a colon polyp is benign and not remove it for biopsy. Currently, all colon polyps are extracted during a colonoscopy and sent to a pathologist for examination, which adds time, expense, and some surgical risk, to the procedure.
Scientific advances at The Scripps Research Institute were key to laying the foundation for the new drug Benlysta® (belimumab), approved today by the U.S. Food and Drug Administration. Benlysta®, which treats the most common type of lupus, is the first in a new class of pharmaceuticals that prevents the body from attacking its own critical tissues.
Invention of the first integrated circularly polarized light detector on a silicon chip opens the door for development of small, portable sensors that could expand the use of polarized light for drug screening, surveillance, optical communications and quantum computing, among other potential applications.
› Verified 9 days ago
Mr. Denis M Cavanagh, MD Radiology Medicare: Not Enrolled in Medicare Practice Location: 300 Riverside Drive E, Suite 4300, Bradenton, FL 34208 Phone: 941-747-3034 Fax: 941-748-8077 | |
Scott Blanchard, RDMS Radiology Medicare: Not Enrolled in Medicare Practice Location: 1505 21st St W, Bradenton, FL 34205 Phone: 941-920-2332 | |
Dr. Steven Lipman, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 8340 Lakewood Ranch Blvd, Bradenton, FL 34202 Phone: 941-782-3053 | |
Robert Howes Montgomery, M.D. Radiology Medicare: Not Enrolled in Medicare Practice Location: 9447 Discovery Ter, #202, Bradenton, FL 34212 Phone: 941-567-4700 | |
Dr. Lawrence George Manco, MD Radiology Medicare: Not Enrolled in Medicare Practice Location: 206 2nd St E, Bradenton, FL 34208 Phone: 941-955-4101 Fax: 941-358-9817 | |
Dr. Richard Gerard Bilodeau, MD Radiology Medicare: Not Enrolled in Medicare Practice Location: 206 2nd Street East, Bradenton, FL 34208 Phone: 941-955-4101 | |
Dr. Sean Xavier Cavanaugh, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 401 Manatee Ave E Ste A, Bradenton, FL 34208 Phone: 941-748-4324 Fax: 941-748-7878 |